Michael Higginbottom

Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and mixed CCK-A/CCK-B antagonists

P. Boden, Michael Higginbottom, David R. Hill et al. · Journal of Medicinal Chemistry · 1993 · 69 citations · Full text

Combinatorial Chemistry, Immunology, Pharmacotherapy +17

Amide bond replacements incorporated into CCK-B selective "dipeptoids"

Christopher I. Fincham, Michael Higginbottom, David R. Hill et al. · Journal of Medicinal Chemistry · 1992 · 61 citations · Full text

PD 176252 — The first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist

Valerie A. Ashwood, Varuni R. Brownhill, Michael Higginbottom et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 50 citations · Full text

Molecular Pharmacology, Biochemistry, Medicine +8

α-Methyl tryptophanylphenylalanines and their arylethylamine “dipeptoid” analogues of the tetrapeptide cholecystokinin (30–33)

David C. Horwell, Barbara Birchmore, Phillip R Boden et al. · European Journal of Medicinal Chemistry · 1990 · 45 citations

α-Methyl Tryptophanylphenylalanines, Medicinal Chemistry, Neuropeptides +10

Rational design of high affinity tachykinin NK1 receptor antagonists

Steven Boyle, Steven Guard, Michael Higginbottom et al. · Bioorganic & Medicinal Chemistry · 1994 · 43 citations

Functional Selectivity, Rational Design, Medicine +6